Repurposing signal: sirolimus scores high on cross-indication evidence

MolecuLens's repurposing engine surfaces sirolimus as a high-confidence candidate across three autoimmune indications — backed by mechanism alignment and published clinical evidence.

MolecuLens's repurposing engine has ranked sirolimus (rapamycin) as a top-five repurposing candidate this week, scoring in the 95th percentile across cross-indication evidence strength. The signal is driven by strong mechanism-of-action alignment in autoimmune and inflammatory conditions — particularly tuberous sclerosis complex-associated manifestations, systemic lupus erythematosus, and lymphangioleiomyomatosis — supported by published Phase II RCT data.

The molecule has an established IP and formulation landscape with several reformulation angles showing freedom-to-operate, making it a candidate for reformulation as well as outright repurposing. Patent-cliff and FTO analysis are available in the full MolecuLens opportunity report. Explore the complete rationale, clinical feasibility assessment, and regulatory pathway analysis in MolecuLens.